New Zealand markets closed

Madrigal Pharmaceuticals, Inc. (MDGL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
229.84+13.79 (+6.38%)
At close: 04:00PM EDT
229.84 0.00 (0.00%)
After hours: 04:01PM EDT

Madrigal Pharmaceuticals, Inc.

Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
267 824 2827
https://www.madrigalpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees376

Key executives

NameTitlePayExercisedYear born
Dr. Rebecca A. Taub M.D.Founder, Chief Medical Officer, President of Research & Development and Director939.83kN/A1952
Mr. Alex G. HowarthExecutive Officer757.26kN/A1969
Mr. William J. SiboldCEO, President & DirectorN/AN/A1966
Mr. Ronald FilippoChief Information OfficerN/AN/AN/A
Ms. Tina E. VenturaChief Investor Relations OfficerN/AN/AN/A
Mr. Clint WallaceChief Human Resources OfficerN/AN/AN/A
Mr. Edward ChiangSenior Vice President of Clinical & Technical OperationsN/AN/AN/A
Mr. Thomas W. HareSenior Vice President of Clinical ManagementN/AN/AN/A
Dr. Robert E. Waltermire Ph.D.Chief Pharmaceutical Development OfficerN/AN/A1964
Dr. Stephen Dodge M.B.A., Pharm.D.Senior Vice President of Global Medical AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Corporate governance

Madrigal Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 4; Board: 9; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.